Clinical Trial Update: A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) [Phase 3]

View source ↗

Summary

A Phase 3 study (ENCORE) evaluating the long-term efficacy and safety of AXS-12 (reboxetine) in narcolepsy with cataplexy and excessive daytime sleepiness has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataplexy
• Excessive Daytime Sleepiness
• Narcolepsy

Drugs mentioned

• AXS-12 (Reboxetine) (reboxetine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Narcolepsy, Cataplexy | Phase 3 | Status: COMPLETED